Research review priorities

Supplement research priorities

These are research priorities, not recommendations. We selected decisions where public interest, plausible benefit, evidence maturity, and safety stakes make a careful synthesis especially useful.

priority dossiers
148
claim-level questions
444
study extraction underway
148

01 / PRIORITY

How priorities were selected

Priority reflects relevance to healthy aging, frequency of real-world use, maturity of human evidence, the cost of a wrong decision, and the need to separate a valid narrow use from broader marketing claims. It does not rank efficacy or imply that everyone should take the product.

02 / EXTRACTION

What happens next

For every question, we screen the PubMed candidate set, connect multiple publications from the same trial, extract population, dose, comparator, duration, outcomes, harms, and funding, then synthesize supportive, mixed, negative, and safety findings together.

Only screened studies enter audited study and participant totals. Search-result counts and the papers listed here as questions never become evidence by themselves.
66

Casein protein

Review stage
Extracting studies
audited research papers
3

Why this is a research priority

Casein is promoted for a special pre-sleep anabolic window, but timing trials are small and often show that daily protein adequacy matters more than bedtime ingestion.

Questions being reviewed
  1. Does pre-sleep casein improve long-term muscle and strength more than the same dose earlier in the day?
  2. Does casein improve next-day soreness, performance, or clinically meaningful recovery?
  3. Does bedtime casein alter appetite, food intake, metabolism, or fat loss?
Open evidence dossier
67

Soy protein

Review stage
Extracting studies
audited research papers
3

Why this is a research priority

Soy protein has a modest LDL-lowering effect and can support training adaptations, but source comparisons change when leucine and total protein are matched.

Questions being reviewed
  1. How much does replacing non-soy protein with soy protein lower LDL and total cholesterol?
  2. Does soy support resistance-training gains comparably to whey when dose and leucine are matched?
  3. Do short lipid or body-composition changes establish cardiovascular or broader health outcomes?
Open evidence dossier
68

Pea protein

Review stage
Extracting studies
audited research papers
3

Why this is a research priority

Pea protein can be a practical alternative to whey, but trials are few, often manufacturer-funded, and frequently lack a nonprotein control or rely on subgroup and biomarker findings.

Questions being reviewed
  1. Does pea protein add muscle or strength beyond resistance training and an adequate diet?
  2. Is pea protein comparable with whey when total protein, leucine, and calories are matched?
  3. Do soreness or performance improve, and are findings replicated independently of manufacturers?
Open evidence dossier
69

Lactobacillus rhamnosus GG (LGG)

Review stage
Extracting studies
audited research papers
3

Why this is a research priority

LGG is a specific strain whose pooled pediatric gastroenteritis signal is heterogeneous and conflicts with a large, rigorous null U.S. trial.

Questions being reviewed
  1. Does LGG shorten acute pediatric gastroenteritis in the population and care setting at issue?
  2. Does LGG prevent antibiotic-associated diarrhea, and how robust are the pediatric estimates?
  3. Which strain identity, viable dose, host risks, and product-storage conditions constrain use?
Open evidence dossier
70

Bifidobacterium animalis subsp. lactis

Review stage
Extracting studies
audited research papers
2

Why this is a research priority

B. animalis subsp. lactis includes distinct strains, while two substantial HN019 constipation trials failed their prespecified primary analyses despite an earlier post hoc signal.

Questions being reviewed
  1. Does a defined B. animalis subsp. lactis strain improve complete spontaneous bowel movements in functional constipation?
  2. Are effects reproducible at the labeled strain, viable dose, duration, and baseline stool frequency?
  3. What host-risk precautions apply, and are results independently replicated beyond manufacturer-linked trials?
Open evidence dossier

03 / SOURCES

Research standards

The review begins with federal evidence summaries and PubMed records, then moves to trial-level extraction. Product claims or another publisher’s evidence grade are not copied into the ledger.

NIH Office of Dietary Supplements ↗PubMed / NCBI ↗NCCIH ↗